NGHIÊN CỨU SỰ BIẾN ĐỔI NỒNG ĐỘ HORMON TSH, FT3, FT4 TRÊN BỆNH NHÂN SA SÚT TRÍ TUỆ

Việt Nguyễn Thị; An Nguyễn Thị Thái; Huy Vũ Quang

doi:10.59354/ydth175.2021.96

Keywords:

dementia, mild cognitive impairment, Alzheime disease, thyroid hormone

Abstract

Background: Thyroid dysfunction is a common condition in the elderly. Many studies have shown that changes in hormone concentration of TSH, FT3, FT4 are related to the pathogenesis of Alzheimer disease and other types of dementia.

Objectives: Investigation into the change in hormone concentration of TSH, FT3, FT4 in dementia patients including mild cognitive impairment (MCI) and Alzheimer disease (AD) compared with the non-dementia group.

Object and method: A cross-sectional study performed on 224 patients divided into two groups. The study group consisted of 112 dementia patients (according to the DSM-V diagnostic criteria) and the control group with 112 non-dementia patients. TSH, FT3, FT4 concentrations was measured on patients in each group to find out the association with dementia. The research was conducted at the Memory and Dementia Unit, April 30 Hospital from November 2020 to May 2021.

Results: The mean concentration of TSH in the dementia group was 1.40 ± 0.95 μIU/ml, which lower than the non-dementia group was 1.71 ± 0.94 (p=0.014). In the dementia group, the prevalence of decrease in TSH level was 8.9% and increase in FT4 level was 9.8%, compared with the non-dementia group was 1.8% (p=0.038) and 0.9% (p = 0.005), respectively. More specific, in the MCI group, the mean concentration of TSH was 1.32 ± 0.47 μIU/ml, which lower than the non-dementia group was 1.71 ± 0.94 μIU/ml (p = 0.025). In the AD group, the mean concentration of FT4 was 0.92 ± 0.18 ng/dL, which higher than the non-dementia group was 0.89 ± 0.11 ng/dL (p < 0.001).

Conclusion: This study has found that generally the dementia patients had higher FT4 and lower TSH levels than the non-dementia patients. The concentration of TSH in the MCI patients was lower than the non-dementia patients and the concentration of FT4 in the AD patients was higher than that levels in the non-dementia patients.

References

Z. S. Tan, R. S. Vasan (2009) “Thyroid function and Alzheimer’s disease”. J Alzheimers Dis, 16 (3), 503-7.

B. B. Yeap, H. Alfonso, S. A. Chubb, G. Puri, G. J. Hankey, L. Flicker, et al. (2012) “Higher free thyroxine levels predict increased incidence of dementia in older men: the Health in Men Study”. J Clin Endocrinol Metab, 97 (12), E2230-7.

L. A. van Osch, E. Hogervorst, M. Combrinck, A. D. Smith (2004) “Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease”. Neurology, 62 (11), 1967-71.

Dale Bredesen (2017) The end of Alzheimer’s: The first program to prevent and reverse cognitive decline, Penguin,

David S. Cooper, Mary H. Samuels (2020) “Hyperthyroidism and Dementia”. Thyroid, 30 (5), 648-650.

AK Thakur, P Kamboj, K Goswami (2018) “Pathophysiology and management of alzheimer’s disease: an overview”. J Anal Pharm Res, 9 (2), 226- 235.

Isabela M Benseñor, Paulo A Lotufo, Paulo R Menezes, Márcia Scazufca (2010) “Subclinical hyperthyroidism and dementia: the Sao Paulo ageing & Health study (SPAH)”. BMC public health, 10 (1), 1-8.

Longfei Jia, Yifeng Du, Lan Chu, Zhanjun Zhang, Fangyu Li, Diyang Lyu, et al. (2020) “Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study”. The Lancet Public Health, 5 (12), e661-e671.

Stefano Mariotti, Giuseppe Barbesino, Patrizio Caturegli, Luigi Bartalena, Paolo Sansoni, Francesco Fagnoni, et al. (1993) “Complex alteration of thyroid function in healthy centenarians”. The Journal of Clinical Endocrinology & Metabolism, 77 (5), 1130-1134.

Yue Wu, Yuqing Pei, Fei Wang, Danfei Xu, Wei Cui (2016) “Higher FT4 or TSH below the normal range are associated with increased risk of dementia: a meta-analysis of 11 studies”. Scientific reports, 6 (1), 1-8.

Jae-Min Kim, Robert Stewart, Seon-Young Kim, Kyung-Yeol Bae, Su-Jin Yang, Sung-Wan Kim, et al. (2010) “Thyroid stimulating hormone, cognitive impairment and depression in an older Korean population”. Psychiatry investigation, 7 (4), 264.

Sylvia Annerbo, Lars-Olof Wahlund, Johan Lökk (2006) “The significance of thyroid-stimulating hormone and homocysteine in the development of Alzheimer’s disease in mild cognitive impairment: a 6-year follow-up study”. American Journal of Alzheimer’s Disease & Other Dementias®, 21 (3), 182-188.

F. J. de Jong, K. Masaki, H. Chen, A. T. Remaley, M. M. Breteler, H. Petrovitch, et al. (2009) “Thyroid function, the risk of dementia and neuropathologic changes: the Honolulu-Asia aging study”. Neurobiol Aging, 30 (4), 600-6.

Q Miao, S Zhang, YH Guan, HY Ye, ZY Zhang, QY Zhang, et al. (2011) “Reversible changes in brain glucose metabolism following thyroid function normalization in hyperthyroidism”. American Journal of Neuroradiology, 32 (6), 1034-1042.